COAG Stock Forecast & Price Target

Hemab Therapeutics Hldgs is a clinical-stage biotechnology company with a focus on developing therapies for the treatment of blood coagulation disorders. The company's flagship candidate, sutacimig, has shown clinically meaningful and sustained bleed reduction in clinical trials for the treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company also has promising preclinical data for HMB-003, a long-acting plasmin inhibitor, and is exploring its potential in treating other bleeding disorders such as heavy menstrual bleeding. The company has a strong pipeline and potential upside from additional indications and assets in development. While there are risks such as safety concerns, efficacy issues, and competition, the company's strong data and progressive pipeline make it a solid investment with potential for future growth.

Hemab Therapeutics Hldgs is currently overvalued according to our SOTP analysis, with an 8x multiple of estimated 2033/34 worldwide sales of sutacimig in GT, an 8x multiple of estimated 2034/35 worldwide sales of sutacimig in FVIID, and an 8x multiple of estimated 2033/34 worldwide sales of HMB-002 in VWD. This, combined with a limited pipeline and increased competition in the hemophilia market, leads to a negative outlook on the stock.